tesamorelin take to work: Frequently asked questions

Tesamorelin's 26–38 minute half-life means GH pulsatility returns to baseline within hours of a missed dose. Skipping even two consecutive doses resets IGF-1 accumulation, effectively restarting the 7–14 day ramp-up period. Research protocols must build in compliance tracking. Missed doses aren't just noise, they're structural failures that invalidate timeline assumptions. Wearable injection trackers or witnessed dosing schedules are standard in rigorous tesamorelin trials for this reason.

End the trial at week 8 and you'll capture hormonal changes but miss the body composition effect entirely. The pivotal Egrifta trials measured VAT at baseline, week 13, and week 26 specifically because earlier imaging showed minimal detectable change. If budget or participant retention forces an early endpoint, pivot to IGF-1 or insulin sensitivity markers rather than claiming tesamorelin failed to reduce fat. The timeline didn't allow for it.

Tesamorelin lyophilised powder is stable at room temperature before reconstitution, but once mixed with bacteriostatic water it must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible peptide degradation. The GHRH analogue structure is particularly fragile at the N-terminal modification site. A research cohort using improperly stored peptide will show blunted or absent GH response within the first week, which is distinguishable from proper dosing by measuring acute GH levels post-injection.

Continue dosing as prescribed. The clinical trial timeline shows minimal measurable VAT reduction before week 10–12, even in responders. Early-phase absence of visible change does not predict non-response. Serum IGF-1 testing at week 4–6 can confirm that the peptide is stimulating GH secretion. If IGF-1 is elevated compared to baseline, the upstream mechanism is working and downstream fat loss will follow with continued dosing.

Inconsistent dosing during the titration phase delays the timeline for measurable results but doesn't negate efficacy once consistent administration resumes. Tesamorelin's effect is cumulative. Missing 3–5 doses in a 26-week protocol adds approximately 1 week to the time required to reach peak effect. The bigger risk is that inconsistent early dosing may reduce IGF-1 elevation enough that patients mistakenly conclude the peptide isn't working and discontinue prematurely.

This is common and reflects the difference between imaging-based fat quantification and anthropometric measures. Visceral fat sits deep within the abdominal cavity, surrounding organs. Losing 10–15% of VAT may produce only 1–2 cm reduction in waist circumference depending on body composition, subcutaneous fat distribution, and abdominal wall muscle mass. DEXA or CT imaging is the gold standard for tracking tesamorelin's effect; waist measurement is a secondary marker that lags behind the actual metabolic change.